[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophageal-cancer-esc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophageal-cancer-esc":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,77,101,122,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100637944","ai-based-risk-prediction-model-for-upper-digestive-tract-cancer-100637944",false,"NCT07605312","AI-Based Risk Prediction Model for Upper Digestive Tract Cancer","Development of Artificial Intelligence Risk Prediction Model for Upper Digestive Tract Cancer Using High Resolution Endoscopic Image, Digital Pathology, Genetics, and Oro-gastro-intestinal Microbiota.","Inclusion Criteria:\n\n* Patients undergoing upper gastrointestinal endoscopy.\n* Patients with at least one of the following conditions or indications:\n\n  * Previous or current Helicobacter pylori infection (confirmed by serology, histopathology, urea breath test, rapid urease test, or stool antigen test);\n  * Dyspeptic symptoms;\n  * Gastroesophageal reflux disease;\n  * History of oral, oropharyngeal, or hypopharyngeal squamous cell carcinoma;\n  * Barrett's esophagus;\n  * Gastric premalignant lesions (intestinal metaplasia or atrophic gastritis);\n  * Gastric subepithelial lesions.\n\nExclusion Criteria:\n\n\\-",true,"ALL","40 Years",{"count":20,"type":21},10000,"ESTIMATED","10 Years","OBSERVATIONAL","Upper digestive tract cancers are often preceded by pre-malignant lesions, but there is limited evidence regarding optimal risk prediction models and screening strategies for disease progression and cancer development. This prospective multicenter cohort study aims to establish a longitudinal database integrating clinical information, endoscopic findings, pathology, genetics, epigenetics, and gastrointestinal microbiota data from subjects undergoing upper digestive tract endoscopy.\n\nThe study will develop explainable artificial intelligence (AI)-based risk prediction models to identify factors associated with disease progression, treatment response, and cancer development. Participants will be followed longitudinally to evaluate changes in lesion severity and clinical outcomes.",[26,27,28,29,30,31],"Gastric Cancer (GC)","Premalignant Lesion","Gastric Intestinal Metaplasia","Atrophic Gastritis","Dysplasia Stomach","Esophageal Cancer (EsC)","NOT_YET_RECRUITING","2026-05-25",{"date":35,"type":36},"2026-05-28","ACTUAL",{"date":38,"type":21},"2026-05-18",{"date":40,"type":21},"2030-05-18",{"name":42,"class":43},"National Taiwan University Hospital","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":23,"phases":4,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100570957","semmelweis-esophageal-cancer-study-noninvasive-prognostic-parameters-in-patients-with-oesophageal-and-esophagogastric-junction-cancer-100570957","NCT06713993","Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer","Noninvasive Testing Procedures, Role of Biomarkers and Anticancer Treatments in Esophageal and Esophagogastric Cancer Survival and Quality of Life of Patients With Cancer of the Esophageopharyngeal and Oesophageophageophageal Junction","Inclusion Criteria:\n\n* Age over 18 years\n* Diagnosis of new-onset esophageal, esophagogastric junction tumor\n* Elective curative surgery (open\u002Flaparoscopic regardless of surgical technique)\n* Patients who have not yet received oncological treatment for their present disease\n\nExclusion Criteria:\n\n* Lack of consent\n* Lack of cooperation\n* Contraindications for some studies: If MR scan is contraindicated, cardiac MR scan is not performed","18 Years",{"count":53,"type":21},100,"5 Years","The objective of this observational study was to gain a deeper understanding of the epidemiology of the disease in Hungary through a broad analysis of patients with new-onset esophageal-oesophageal-stomach junction tumors, and to identify key parameters that could potentially influence the outcome of the disease and are closely correlated with morbidity and mortality. The investigators' primary objective is to identify potential factors and conditions that could be influenced and modified to enhance the disease outcome.\n\nMain questions:\n\n1. What are the measurable changes in performance, workload, nutritional status, cardiac function, mental status in the patients studied?\n2. What is the time course of the changes during and after treatment?\n3. Which pathological parameters are associated with disease outcome and which are potential points of intervention to improve the course of the disease?\n\nPatients will undergo a detailed physical and nutritional assessment, non-invasive imaging tests and several questionnaires in addition to the usual pre- and post-operative examinations.",[31],[58,59,60,61,62,63,64,65],"Esophageal cancer","heart failure","sarcopenia","malnutrition","frailty","heart function","Esophageal cancer surgery","cardiovascular abnormalities","RECRUITING","2026-04-23",{"date":69,"type":36},"2026-04-24",{"date":71,"type":36},"2024-09-10",{"date":73,"type":21},"2034-09-10",{"name":75,"class":43},"Semmelweis University",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100609165","phase-3-patient-reported-symptom-care-versus-usual-care-after-esophageal-cancer-surgery-a-single-center-phase-3-randomized-trial-100609165","NCT07211009","Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized Trial","A Single-Center, Randomized, Controlled, Phase III Clinical Study of Patient-Reported Outcome-Based Symptom Management Versus Conventional Management in Postoperative Esophageal Cancer Patients","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. Pathologically confirmed esophageal cancer.\n3. Planned to undergo curative (radical) surgical resection.\n4. R0 resection.\n5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1.\n6. Adequate function of major organs.\n7. Willing to complete questionnaire surveys.\n8. Voluntarily agrees to participate and signs the informed consent form.\n9. Good compliance and able to complete follow-up as scheduled.\n\nExclusion Criteria:\n\n1. Human immunodeficiency virus (HIV) infection.\n2. Psychiatric disorder.\n3. Any other malignancy within the past 5 years (except completely cured carcinoma in situ of the cervix or basal cell\u002Fsquamous cell carcinoma of the skin).\n4. Patient ultimately did not undergo curative (radical) surgical resection.\n5. Any unstable systemic disease (including active, uncontrolled gastrointestinal ulcer; active infection; grade 4 hypertension; unstable angina; congestive heart failure; unstable cerebrovascular disease; thrombotic disease; hepatic, renal, or metabolic disease; or unhealed fracture\u002Fwound as determined by the surgeon).\n6. Difficulty in communication or inability to comply with long-term follow-up.\n7. Any other condition deemed unsuitable by the investigator.","75 Years",{"count":86,"type":21},240,"INTERVENTIONAL",[89],"PHASE3","Symptom management is fundamental to clinical care, and symptom monitoring is an effective means to detect potential adverse events early and prevent serious complications. Extensive studies show that symptom management based on patient-reported outcomes (PROs) can reduce symptom burden, improve functional status and quality of life, lower emergency visits and readmissions, and even prolong survival. However, in the field of esophageal cancer surgery, prospective clinical studies assessing the feasibility of postoperative PRO-based symptom management remain lacking. This project proposes a randomized controlled trial (RCT) in China to systematically evaluate the effectiveness and feasibility of PRO-based symptom management after esophageal cancer surgery. Through this clinical study, we aim to assess both the impact and the implementability of introducing a proactive, patient-centered PRO symptom-management model into esophageal surgical care.",[31],"2025-09-29",{"date":94,"type":36},"2025-10-07",{"date":96,"type":21},"2025-10-15",{"date":98,"type":21},"2028-12-31",{"name":100,"class":43},"Sichuan University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":84,"enrollmentInfo":107,"targetDuration":4,"studyType":87,"phases":109,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":76},"100582892","phase-2-a-single-arm-open-single-center-exploratory-study-of-adebrelimab-shr-1316-in-combination-with-chemotherapy-for-the-perioperative-treatment-of-locally-advanced-resectable-esophageal-squamous-carcinoma-100582892","NCT06869213","A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma","Inclusion Criteria:\n\n1. Aged 18-75 years old, regardless of gender；\n2. Surgically resectable locally advanced squamous cell carcinoma of the esophagus confirmed by histology or cytology (pre-treatment clinical stage cT1b-cT2, N+ or cT3-cT4a, ANY N according to the 8th edition of AJCC staging);\n3. Presence of measurable and\u002For non-measurable lesions as defined by the criteria for evaluating the efficacy of solid tumors (RECIST v1.1);\n4. No prior antitumor therapy for esophageal cancer, including chemotherapy, radiotherapy (including planned radiotherapy during the study period), hormone therapy, and immunotherapy;\n5. ECOG PS 0 to 1 point;\n6. No contraindication to surgery as evaluated by various organ function tests;\n7. Prior to treatment, the following laboratory tests to confirm that bone marrow, liver and kidney function meet the requirements for participation in the study (requiring no blood transfusion or use of hematopoietic stimulating factors (including G-CSF, GM-CSF , EPO, and TPO, etc.) within 14 days prior to screening):\n\n   * Hemoglobin ≥ 90 g\u002FL;\n   * White blood cell count ≥ lower limit of laboratory normal;\n   * Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL;\n   * Platelet count ≥100×109\u002FL;\n   * Total bilirubin ≤ 1.5 x upper limit of normal (ULN);\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN;\n   * Prothrombin time ≤ 16 seconds and International Normalized Ratio (INR) ≤ 1.5 x ULN;\n   * Creatinine ≤ 1.5 x ULN and Cr clearance ≥ 50 mL\u002Fmin (calculated using the Cockcroft-Gault formula);\n8. Must understand and voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n1. malignant tumors other than esophageal cancer within 5 years prior to enrollment (cured limited tumors are not excluded, including cervical carcinoma in situ, basal cell carcinoma of the skin, and carcinoma in situ of the prostate gland; patients with prostate cancer who received hormone therapy and obtained DFS for more than 5 years are not excluded)；\n2. Comorbid serious cardiac and cerebrovascular diseases:\n\n   * Congestive heart failure, unstable angina, myocardial infarction, poorly controlled arrhythmia, or cerebrovascular accident of New York Heart Association (NYHA) class II or higher within 12 months prior to enrollment.\n   * Medication-uncontrolled hypertension (systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100 mmHg) (based on the average of ≥2 measurements)\n   * Previous hypertensive crisis or hypertensive encephalopathy\n3. Prior history of interstitial lung disease or pneumonia requiring steroid therapy at enrollment；\n4. Have a blood-borne infectious disease, including, but not limited to, hepatitis B virus carrier, hepatitis C, syphilis, or HIV;\n5. Previous severe allergy to chemotherapeutic agents (paclitaxel or carboplatin) or to any of the monoclonal antibodies;\n6. Active autoimmune disease requiring systemic therapy (i.e., immunomodulatory drugs, corticosteroid drugs, or immunosuppressive drugs) within the past 2 years; however, alternative therapies (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) are not considered systemic and are permitted and enrollment is allowed;\n7. Women during pregnancy;\n8. Patients who, in the opinion of the investigator, are not suitable for participation in this study, based on a comprehensive assessment.",{"count":108,"type":21},30,[110],"PHASE2","This study is a prospective, observational clinical study. In this study, 30 patients with resectable locally advanced esophageal squamous carcinoma will be prospectively enrolled and treated with adebrelimab (SHR-1316) combined with nab-paclitaxel and cisplatin preoperatively and adebrelimab (SHR-1316) single-agent adjuvant therapy postoperatively, to observe the efficacy and safety of this treatment modality, and to provide clinical evidence for the use of PD-L1 monoclonal antibody in perioperative treatment of esophageal cancer.",[31],"2025-09-28",{"date":115,"type":36},"2025-10-02",{"date":117,"type":36},"2025-03-31",{"date":119,"type":21},"2027-12-31",{"name":121,"class":43},"Peking University Cancer Hospital & Institute",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":87,"phases":131,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100601003","non-intubated-versus-intubated-anesthesia-in-thoracoscopic-esophagectomy-for-esophageal-cancer-100601003","NCT07104838","Non-intubated Versus Intubated Anesthesia in Thoracoscopic Esophagectomy for Esophageal Cancer","Efficacy and Safety of Non-intubated Versus Intubated Anesthesia in Thoracoscopic Radical Esophagectomy for Esophageal Cancer: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Diagnosed with resectable middle or lower thoracic esophageal squamous cell carcinoma or adenocarcinoma (clinical stage I-III)\n* Scheduled to undergo thoracoscopic esophagectomy\n* American Society of Anesthesiologists (ASA) score ≤ III\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n* Preoperative pulmonary function test with FEV₁ ≥ 50% predicted\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Severe risk of aspiration due to reflux, gastric retention, or hiatal hernia\n* Body mass index (BMI) ≥ 30 kg\u002Fm²\n* Extensive pleural adhesions discovered preoperatively\n* History of upper thoracic or intrathoracic surgery\n* Pregnancy or lactation\n* Known allergy or intolerance to anesthetic agents",{"count":130,"type":21},500,[132],"NA","This is a prospective, single-center, non-inferiority randomized controlled trial designed to evaluate the perioperative safety and feasibility of non-intubated spontaneous ventilation anesthesia (NIV) compared to conventional intubated mechanical ventilation anesthesia (IMV) in patients undergoing thoracoscopic esophagectomy for esophageal cancer. The study will be conducted at the First Affiliated Hospital of Guangzhou Medical University and aims to assess whether the non-intubated approach can offer comparable or better outcomes in terms of intraoperative and postoperative complications, anesthetic drug consumption, recovery parameters, and overall postoperative rehabilitation.\n\nEligible patients aged 18 to 75 years with resectable middle or lower thoracic esophageal squamous cell carcinoma or adenocarcinoma (stage I-III) will be randomly assigned (1:1) to receive either NIV using a laryngeal mask airway or IMV with a double-lumen endotracheal tube. Both groups will undergo the same thoracoscopic and laparoscopic surgical procedures, and anesthesia will be managed with standardized protocols. The primary outcome is the incidence of intraoperative and postoperative complications, including hypoxemia, hypercapnia, respiratory failure, and the need for conversion to intubation. Secondary outcomes include anesthetic drug dosage, intraoperative hemodynamic stability, postoperative pain scores, time to ambulation, length of hospital stay, and 30-day readmission rate.\n\nThis trial complies with the Declaration of Helsinki. Written informed consent will be obtained from all participants prior to enrollment.",[31],"2025-09-23",{"date":137,"type":36},"2025-09-25",{"date":139,"type":21},"2025-10-01",{"date":141,"type":21},"2026-12-01",{"name":143,"class":43},"The First Affiliated Hospital of Guangzhou Medical University",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":87,"phases":153,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100606790","health-informatics-and-resistance-exercise-for-symptom-management-and-quality-of-life-in-post-esophagectomy-patients-100606790","NCT07180134","Health Informatics and Resistance Exercise for Symptom Management and Quality of Life in Post-Esophagectomy Patients","Effects of Health Informatics for Symptom Management and Resistance Exercise Strategies on Quality of Life and Sarcopenia in Post-Esophagectomy Patients With Esophageal Cancer: A Mixed-Methods Study","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosed with esophageal cancer and having undergone esophagectomy\n* Postoperative pathological report confirms R0 resection (complete tumor removal)\n* Able to be discharged after surgery\n* With or without adjuvant chemoradiotherapy\n* Clear consciousness and able to communicate in Mandarin or Taiwanese\n\nExclusion Criteria:\n\n* Presence of severe cardiovascular disease or psychiatric disorders\n* Inability to communicate in Mandarin Chinese or Taiwanese\n* Disease progression during the intervention period that prevents continuation of participation.",{"count":152,"type":21},90,[132],"Participants are invited to take part in a research study. In accordance with the requirements of the health authorities, participants must be informed of the purpose of the study and its potential risks. Participation is voluntary, and each participant is free to decide whether or not to enroll. The study may be discussed with trusted individuals, and sufficient time may be taken to consider the decision. If any part of this consent form is unclear, questions may be directed to the principal investigator or the research team, who will provide an explanation.\n\nIf a participant chooses not to participate, appropriate treatment will still be provided. Even if a participant agrees to participate initially, withdrawal is allowed at any time without affecting medical rights or the care that should be received.",[31,156,157],"Sarcopenia","Quality of Life",[159,160,161,162],"Esophagectomy","Nutrition","Quality of life","Exercise","2025-09-16",{"date":165,"type":36},"2025-09-18",{"date":139,"type":21},{"date":168,"type":21},"2027-07-31",{"name":170,"class":43},"Chang Gung Memorial Hospital"]